Paper39199550
Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies.
Rahman M and 7 others. Cancers (Basel), 2024. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies. Papers, record 39199550. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39199550
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| NRF-2020R1I1A2066868 | Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education | PubMed | ||
| 2020R1A5A2019413 | National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) | PubMed | ||
| RS-2020-KH087790 | Ministry of Health & Welfare, Republic of Korea | PubMed | ||
| RS-2024-00350362 | national Research Foundation of korea (NRF) grant funded by the korea Government (MSIT) | PubMed |
Source PubMed
References217
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24278513 | Berberine inhibited radioresistant effects and enhanced anti-tumor effects in the irradiated-human prostate cancer cells. | Toxicol Res | 2010 | https://conductscience.org/library/papers/24278513 | PubMed |
| 2 | 38224119 | A bis-quinoline ruthenium(II) arene complex with submicromolar cytotoxicity in castration-resistant prostate cancer cells. | Chem Commun (Camb) | 2024 | https://conductscience.org/library/papers/38224119 | PubMed |
| 3 | 31801262 | Curcumin and Its Derivatives as Potential Therapeutic Agents in Prostate, Colon and Breast Cancers. | Molecules | 2019 | https://conductscience.org/library/papers/31801262 | PubMed |
| 4 | 25649018 | Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/25649018 | PubMed |
| 5 | 16101488 | Etoposide, topoisomerase II and cancer. | Curr Med Chem Anticancer Agents | 2005 | https://conductscience.org/library/papers/16101488 | PubMed |
| 6 | 37446908 | Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications. | Molecules | 2023 | https://conductscience.org/library/papers/37446908 | PubMed |
| 7 | 18281560 | Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/18281560 | PubMed |
| 8 | 32710433 | Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression. | Cell Oncol (Dordr) | 2020 | https://conductscience.org/library/papers/32710433 | PubMed |
| 9 | 39341127 | Nanodelivery system of traditional Chinese medicine bioactive compounds: Application in the treatment of prostate cancer. | Phytomedicine | 2024 | https://conductscience.org/library/papers/39341127 | PubMed |
| 10 | 27499349 | Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells. | Int J Oncol | 2016 | https://conductscience.org/library/papers/27499349 | PubMed |
| 11 | 29065980 | Genistein: Its role in metabolic diseases and cancer. | Crit Rev Oncol Hematol | 2017 | https://conductscience.org/library/papers/29065980 | PubMed |
| 12 | 34354111 | Conformational dynamics of androgen receptors bound to agonists and antagonists. | Sci Rep | 2021 | https://conductscience.org/library/papers/34354111 | PubMed |
| 13 | 26137992 | Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. | Sci Rep | 2015 | https://conductscience.org/library/papers/26137992 | PubMed |
| 14 | 36172195 | Synergistic effects of natural products in combination with anticancer agents in prostate cancer: A scoping review. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36172195 | PubMed |
| 15 | 17326044 | Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. | Cancer | 2007 | https://conductscience.org/library/papers/17326044 | PubMed |
| 16 | 25325026 | Honokiol, a constituent of Magnolia species, inhibits adrenergic contraction of human prostate strips and induces stromal cell death. | Prostate Int | 2014 | https://conductscience.org/library/papers/25325026 | PubMed |
| 17 | 35829924 | Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends. | Clin Drug Investig | 2022 | https://conductscience.org/library/papers/35829924 | PubMed |
| 18 | 20807808 | Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. | Cancer Res | 2010 | https://conductscience.org/library/papers/20807808 | PubMed |
| 19 | 19536890 | Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. | Cancer | 2009 | https://conductscience.org/library/papers/19536890 | PubMed |
| 20 | 26912557 | Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. | Ann Oncol | 2016 | https://conductscience.org/library/papers/26912557 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42280440 | Herbal Neurotherapeutics for Cognitive Disorders: Integrative Mechanisms Linking Neurotransmitter Systems, Neurodegeneration, and the Gut-Brain Axis. | Nutrients | 2026 | https://conductscience.org/library/papers/42280440 | PubMed |
| 42047726 | Rewired lipid metabolism in castration-resistant prostate cancer: molecular interplay between glucose metabolism and sterol synthesis. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42047726 | PubMed |
| 41827723 | Bioactive Natural Products Targeting Androgen Receptor Signaling in Prostate Cancer: A Systematic Review. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41827723 | PubMed |
| 41827159 | Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine. | J Clin Med | 2026 | https://conductscience.org/library/papers/41827159 | PubMed |
| 41598623 | Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone. | J Clin Med | 2026 | https://conductscience.org/library/papers/41598623 | PubMed |
| 41596531 | Prostate Cancer, JAK/STAT3 Dysregulation, and Flavonoids: Is There a Possible Link? | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41596531 | PubMed |
| 41503910 | CD24 and Mutant p53: Emerging Therapeutic Targets in Prostate Cancer Progression. | Anticancer Agents Med Chem | 2026 | https://conductscience.org/library/papers/41503910 | PubMed |
| 41151861 | Verbascoside Suppresses Epithelial-Mesenchymal Transition and Mitochondrial Biogenesis by Targeting Anti-senescence Signaling in Castration-resistant Prostate Cancer. | Cancer Genomics Proteomics | 2025 | https://conductscience.org/library/papers/41151861 | PubMed |
| 41020838 | Revisiting Curcumin in Cancer Therapy: Recent Insights into Molecular Mechanisms, Nanoformulations, and Synergistic Combinations. | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/41020838 | PubMed |
| 40626308 | Unveiling the therapeutic potential of natural products in Alzheimer's disease: insights from in vitro, in vivo, and clinical studies. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40626308 | PubMed |
| 40498093 | Overcoming resistance mechanisms in cancer immunotherapy-novel approaches and combinations. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | https://conductscience.org/library/papers/40498093 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| AR | 367 | PubTator's text mining | https://conductscience.org/library/genes/367 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39199550
GET https://conductscience.org/api/papers/v1/39199550/references?page=2